16 Pharmaceuticals Stocks to Sell Now

This week, the overall grades of 16 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Valeant Pharmaceuticals International, Inc. (VRX) slips from a C to a D this week. Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VRX stock.

Novartis AG Sponsored ADR (NVS) earns a D this week, moving down from last week’s grade of C. Novartis AG Sponsored ADR manufactures pharmaceutical and consumer healthcare products. For more information, get Portfolio Grader’s complete analysis of NVS stock.

Mallinckrodt Plc’s (MNK) rating weakens this week, dropping to a D versus last week’s C. For more information, get Portfolio Grader’s complete analysis of MNK stock.

Slipping from a C to a D rating, GW Pharmaceuticals PLC Sponsored ADR (GWPH) takes a hit this week. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

Endo International Plc (ENDP) declines this week from a C to a D. Endo International Plc provides specialty healthcare solutions in the United States and internationally. The company also gets F’s in earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ENDP stock.

This week, Merck & Co., Inc. (MRK) drops from a C to a D rating. Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MRK stock.

This is a rough week for Flamel Technologies SA Sponsored ADR (FLML). The company’s rating falls to D from the previous week’s C. Flamel Technologies SA Sponsored ADR develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. The company also gets F’s in earnings revisions, earnings surprise, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLML stock.

Ocular Therapeutix Inc (OCUL) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OCUL stock.

Cardiome Pharma Corp. (CRME) is having a tough week. The company’s rating falls from a C to a D. Cardiome Pharma Corp. focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRME stock.

Tetraphase Pharmaceuticals, Inc. (TTPH) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TTPH stock.

This week, Marinus Pharmaceuticals Inc’s (MRNS) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRNS stock.

SCYNEXIS, Inc. (SCYX) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SCYX stock.

Aratana Therapeutics, Inc. (PETX) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings revisions, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PETX stock.

Parnell Pharmaceuticals Holdings Ltd. (PARN) declines this week from a C to a D. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PARN stock.

Ocera Therapeutics, Inc. (OCRX) gets weaker ratings this week as last week’s D drops to a F. Ocera Therapeutics, Inc. develops novel therapeutics products designed to treat liver and gastrointestinal diseases. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OCRX stock.

This week, Acasti Pharma Inc. Class A (ACST) drops from a C to a D rating. Acasti Pharma Inc. Class A is a pharmaceutical company that develops drugs for cardiovascular diseases. The company also gets F’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ACST stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/01/16-pharmaceuticals-stocks-to-sell-now/.

©2021 InvestorPlace Media, LLC